| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Longevity | 24 | 2025 | 173 | 4.910 |
Why?
|
| Nursing Homes | 16 | 2016 | 64 | 4.160 |
Why?
|
| Geriatrics | 12 | 2024 | 67 | 3.260 |
Why?
|
| Hypertension | 20 | 2024 | 835 | 2.920 |
Why?
|
| Aging | 36 | 2025 | 783 | 2.880 |
Why?
|
| Hawaii | 94 | 2025 | 2011 | 2.860 |
Why?
|
| Aged | 155 | 2025 | 8214 | 2.850 |
Why?
|
| Dementia | 33 | 2022 | 160 | 2.850 |
Why?
|
| Aged, 80 and over | 99 | 2025 | 2853 | 2.520 |
Why?
|
| Genotype | 20 | 2025 | 800 | 2.480 |
Why?
|
| Cognition Disorders | 27 | 2022 | 243 | 2.260 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2024 | 863 | 2.220 |
Why?
|
| Risk Factors | 82 | 2025 | 3994 | 2.090 |
Why?
|
| Japan | 54 | 2025 | 348 | 2.020 |
Why?
|
| Humans | 227 | 2025 | 43102 | 1.950 |
Why?
|
| Male | 169 | 2025 | 23409 | 1.860 |
Why?
|
| Polypharmacy | 5 | 2014 | 27 | 1.840 |
Why?
|
| Cognition | 14 | 2025 | 473 | 1.660 |
Why?
|
| Coronary Artery Disease | 12 | 2024 | 163 | 1.650 |
Why?
|
| Stroke | 11 | 2023 | 340 | 1.620 |
Why?
|
| Alzheimer Disease | 26 | 2023 | 1001 | 1.610 |
Why?
|
| Education, Distance | 3 | 2024 | 46 | 1.600 |
Why?
|
| Coronary Disease | 17 | 2020 | 123 | 1.550 |
Why?
|
| Prospective Studies | 46 | 2025 | 1600 | 1.410 |
Why?
|
| Health Personnel | 3 | 2019 | 277 | 1.300 |
Why?
|
| Curriculum | 8 | 2025 | 318 | 1.290 |
Why?
|
| Clinical Competence | 9 | 2025 | 156 | 1.270 |
Why?
|
| Parkinson Disease | 13 | 2023 | 210 | 1.270 |
Why?
|
| Education, Medical, Graduate | 4 | 2014 | 61 | 1.240 |
Why?
|
| Telemedicine | 2 | 2023 | 234 | 1.220 |
Why?
|
| Interprofessional Relations | 6 | 2024 | 59 | 1.200 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 122 | 1.190 |
Why?
|
| Patient Care Team | 3 | 2022 | 60 | 1.150 |
Why?
|
| Dementia, Vascular | 8 | 2023 | 35 | 1.140 |
Why?
|
| Middle Aged | 88 | 2025 | 12222 | 1.140 |
Why?
|
| Incidence | 31 | 2025 | 1078 | 1.130 |
Why?
|
| Vitamin D | 6 | 2016 | 196 | 1.110 |
Why?
|
| Receptors, Somatotropin | 2 | 2024 | 18 | 1.050 |
Why?
|
| Longitudinal Studies | 30 | 2024 | 1063 | 1.020 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 269 | 1.010 |
Why?
|
| Alcohol Drinking | 7 | 2024 | 609 | 1.000 |
Why?
|
| Cohort Studies | 36 | 2025 | 1759 | 0.950 |
Why?
|
| Pharmacy | 2 | 2024 | 34 | 0.940 |
Why?
|
| Proteinuria | 3 | 2015 | 56 | 0.930 |
Why?
|
| Geriatric Assessment | 11 | 2016 | 66 | 0.890 |
Why?
|
| Risk Assessment | 24 | 2025 | 863 | 0.890 |
Why?
|
| Body Mass Index | 18 | 2025 | 925 | 0.880 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 104 | 0.830 |
Why?
|
| Pesticides | 5 | 2019 | 62 | 0.830 |
Why?
|
| Physician-Patient Relations | 3 | 2017 | 148 | 0.820 |
Why?
|
| Aortic Diseases | 6 | 2025 | 34 | 0.810 |
Why?
|
| Brain | 19 | 2019 | 1472 | 0.800 |
Why?
|
| Physician Executives | 2 | 2013 | 5 | 0.790 |
Why?
|
| Follow-Up Studies | 27 | 2024 | 1067 | 0.770 |
Why?
|
| Palliative Care | 4 | 2020 | 61 | 0.750 |
Why?
|
| Students, Nursing | 1 | 2023 | 38 | 0.750 |
Why?
|
| Homes for the Aged | 2 | 2012 | 19 | 0.720 |
Why?
|
| Needs Assessment | 3 | 2019 | 178 | 0.720 |
Why?
|
| Internship and Residency | 6 | 2025 | 146 | 0.710 |
Why?
|
| Occupational Exposure | 3 | 2019 | 91 | 0.700 |
Why?
|
| Alleles | 7 | 2024 | 352 | 0.700 |
Why?
|
| Life Style | 11 | 2024 | 334 | 0.700 |
Why?
|
| Vitamin D Deficiency | 4 | 2016 | 107 | 0.690 |
Why?
|
| Agricultural Workers' Diseases | 2 | 2019 | 6 | 0.670 |
Why?
|
| Age Factors | 24 | 2020 | 1154 | 0.660 |
Why?
|
| Atrial Flutter | 1 | 2020 | 7 | 0.650 |
Why?
|
| Sleep Apnea, Central | 1 | 2020 | 5 | 0.650 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2020 | 12 | 0.640 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2022 | 40 | 0.640 |
Why?
|
| Occupational Health | 2 | 2019 | 32 | 0.630 |
Why?
|
| Female | 73 | 2025 | 24698 | 0.630 |
Why?
|
| Asia | 10 | 2023 | 98 | 0.630 |
Why?
|
| Lewy Bodies | 11 | 2019 | 30 | 0.630 |
Why?
|
| Medicare | 1 | 2022 | 332 | 0.620 |
Why?
|
| Weight Loss | 6 | 2013 | 137 | 0.620 |
Why?
|
| Cross-Sectional Studies | 30 | 2024 | 3156 | 0.620 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 231 | 0.620 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 495 | 0.620 |
Why?
|
| Communication | 3 | 2025 | 210 | 0.610 |
Why?
|
| Professional-Family Relations | 3 | 2025 | 11 | 0.600 |
Why?
|
| Depression | 8 | 2024 | 863 | 0.600 |
Why?
|
| Internal Medicine | 4 | 2025 | 32 | 0.580 |
Why?
|
| United States | 33 | 2025 | 5205 | 0.580 |
Why?
|
| Postmenopause | 9 | 2025 | 141 | 0.570 |
Why?
|
| Fellowships and Scholarships | 4 | 2014 | 32 | 0.570 |
Why?
|
| Leukocyte Count | 2 | 2015 | 69 | 0.560 |
Why?
|
| Educational Measurement | 4 | 2014 | 102 | 0.550 |
Why?
|
| Humanism | 1 | 2017 | 3 | 0.540 |
Why?
|
| Dietary Supplements | 5 | 2015 | 213 | 0.540 |
Why?
|
| Sarcopenia | 1 | 2017 | 15 | 0.540 |
Why?
|
| Community Health Services | 1 | 2019 | 206 | 0.530 |
Why?
|
| Blood Pressure | 9 | 2020 | 666 | 0.530 |
Why?
|
| Anthropometry | 1 | 2017 | 97 | 0.520 |
Why?
|
| Electrocardiography | 4 | 2023 | 185 | 0.500 |
Why?
|
| Obesity | 7 | 2025 | 1151 | 0.480 |
Why?
|
| Lewy Body Disease | 4 | 2019 | 16 | 0.470 |
Why?
|
| Estrogens, Conjugated (USP) | 6 | 2020 | 11 | 0.460 |
Why?
|
| Proportional Hazards Models | 20 | 2014 | 518 | 0.460 |
Why?
|
| Neuropsychological Tests | 12 | 2022 | 284 | 0.460 |
Why?
|
| Granulocytes | 1 | 2014 | 26 | 0.440 |
Why?
|
| Calcium, Dietary | 2 | 2015 | 65 | 0.440 |
Why?
|
| Activities of Daily Living | 5 | 2025 | 139 | 0.440 |
Why?
|
| Cholesterol | 8 | 2020 | 232 | 0.440 |
Why?
|
| Diet | 7 | 2022 | 826 | 0.430 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2014 | 95 | 0.430 |
Why?
|
| Prevalence | 20 | 2020 | 1612 | 0.420 |
Why?
|
| Terminal Care | 2 | 2016 | 54 | 0.420 |
Why?
|
| Role Playing | 1 | 2013 | 3 | 0.420 |
Why?
|
| Schools, Medical | 2 | 2018 | 208 | 0.420 |
Why?
|
| Long-Term Care | 5 | 2013 | 55 | 0.410 |
Why?
|
| Neutrophils | 1 | 2014 | 145 | 0.410 |
Why?
|
| Adult | 40 | 2025 | 13872 | 0.400 |
Why?
|
| Lipoproteins, HDL | 3 | 2022 | 48 | 0.400 |
Why?
|
| Nursing Staff | 1 | 2012 | 7 | 0.380 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2024 | 734 | 0.380 |
Why?
|
| Waist Circumference | 3 | 2025 | 90 | 0.380 |
Why?
|
| Logistic Models | 12 | 2025 | 1009 | 0.370 |
Why?
|
| Family | 2 | 2013 | 195 | 0.370 |
Why?
|
| Apolipoprotein E4 | 5 | 2025 | 67 | 0.370 |
Why?
|
| Neurofibrillary Tangles | 8 | 2016 | 115 | 0.360 |
Why?
|
| Attitude to Death | 2 | 2020 | 23 | 0.350 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 2 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 245 | 0.350 |
Why?
|
| Retrospective Studies | 14 | 2023 | 2544 | 0.350 |
Why?
|
| Urinary Calculi | 1 | 2011 | 2 | 0.350 |
Why?
|
| Hospitals | 2 | 2010 | 117 | 0.350 |
Why?
|
| Hotlines | 1 | 2011 | 16 | 0.350 |
Why?
|
| Cardiovascular Diseases | 6 | 2021 | 749 | 0.340 |
Why?
|
| Hospitalization | 5 | 2015 | 485 | 0.340 |
Why?
|
| Death | 4 | 2015 | 11 | 0.330 |
Why?
|
| Time Factors | 14 | 2016 | 1857 | 0.330 |
Why?
|
| Disease Progression | 12 | 2025 | 667 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 94 | 0.330 |
Why?
|
| Caregivers | 1 | 2013 | 197 | 0.330 |
Why?
|
| Leadership | 1 | 2011 | 86 | 0.330 |
Why?
|
| Physician's Role | 1 | 2010 | 40 | 0.330 |
Why?
|
| Smoking | 13 | 2022 | 1024 | 0.320 |
Why?
|
| Calcinosis | 4 | 2016 | 62 | 0.320 |
Why?
|
| Cause of Death | 4 | 2017 | 186 | 0.320 |
Why?
|
| Acculturation | 1 | 2012 | 205 | 0.320 |
Why?
|
| Calcium Carbonate | 3 | 2015 | 11 | 0.310 |
Why?
|
| Case-Control Studies | 13 | 2023 | 1285 | 0.310 |
Why?
|
| Health Status | 5 | 2022 | 442 | 0.310 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 310 | 0.300 |
Why?
|
| Eicosapentaenoic Acid | 3 | 2022 | 14 | 0.300 |
Why?
|
| Docosahexaenoic Acids | 3 | 2022 | 19 | 0.300 |
Why?
|
| Death Certificates | 1 | 2009 | 15 | 0.300 |
Why?
|
| Comorbidity | 10 | 2016 | 737 | 0.300 |
Why?
|
| Blood Pressure Determination | 4 | 2020 | 54 | 0.290 |
Why?
|
| Home Care Services | 1 | 2009 | 37 | 0.290 |
Why?
|
| Mortality | 4 | 2016 | 175 | 0.290 |
Why?
|
| Forkhead Transcription Factors | 4 | 2014 | 78 | 0.280 |
Why?
|
| Genetic Variation | 5 | 2021 | 430 | 0.270 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 638 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2020 | 760 | 0.260 |
Why?
|
| Patient Care | 2 | 2022 | 31 | 0.260 |
Why?
|
| Sex Factors | 9 | 2014 | 1028 | 0.260 |
Why?
|
| Gambling | 1 | 2006 | 21 | 0.250 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 287 | 0.250 |
Why?
|
| Adiposity | 2 | 2018 | 157 | 0.250 |
Why?
|
| Disability Evaluation | 4 | 2015 | 73 | 0.250 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2015 | 42 | 0.240 |
Why?
|
| Overweight | 4 | 2025 | 249 | 0.240 |
Why?
|
| Medroxyprogesterone Acetate | 4 | 2020 | 12 | 0.240 |
Why?
|
| Women's Health | 7 | 2022 | 160 | 0.240 |
Why?
|
| Substantia Nigra | 3 | 2015 | 52 | 0.240 |
Why?
|
| Hydrocarbons, Chlorinated | 2 | 2018 | 21 | 0.240 |
Why?
|
| Predictive Value of Tests | 9 | 2015 | 440 | 0.240 |
Why?
|
| Cholesterol, HDL | 4 | 2018 | 99 | 0.240 |
Why?
|
| Motor Activity | 5 | 2013 | 437 | 0.230 |
Why?
|
| Advance Care Planning | 2 | 2016 | 20 | 0.230 |
Why?
|
| Diabetes Mellitus | 6 | 2016 | 539 | 0.230 |
Why?
|
| Educational Status | 4 | 2023 | 339 | 0.220 |
Why?
|
| Apolipoproteins E | 2 | 2022 | 138 | 0.220 |
Why?
|
| Odds Ratio | 7 | 2015 | 587 | 0.220 |
Why?
|
| Republic of Korea | 8 | 2018 | 141 | 0.210 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 20 | 0.200 |
Why?
|
| Carotid Artery Diseases | 2 | 2018 | 26 | 0.200 |
Why?
|
| Aorta | 3 | 2014 | 198 | 0.200 |
Why?
|
| Cholecalciferol | 2 | 2013 | 20 | 0.200 |
Why?
|
| Health Behavior | 3 | 2014 | 575 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 989 | 0.190 |
Why?
|
| Apolipoprotein E2 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 58 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 213 | 0.190 |
Why?
|
| Socioeconomic Factors | 4 | 2013 | 1234 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 76 | 0.180 |
Why?
|
| Chronic Disease | 4 | 2014 | 549 | 0.180 |
Why?
|
| Phospholipids | 1 | 2022 | 70 | 0.180 |
Why?
|
| Pacific Islands | 1 | 2022 | 123 | 0.180 |
Why?
|
| Language | 3 | 2010 | 185 | 0.180 |
Why?
|
| Medical Audit | 2 | 2012 | 26 | 0.180 |
Why?
|
| Caenorhabditis elegans | 1 | 2022 | 80 | 0.180 |
Why?
|
| Learning | 1 | 2023 | 161 | 0.180 |
Why?
|
| Program Evaluation | 2 | 2013 | 359 | 0.180 |
Why?
|
| Eating | 2 | 2021 | 167 | 0.170 |
Why?
|
| Exercise | 2 | 2025 | 692 | 0.170 |
Why?
|
| Insulin Resistance | 3 | 2019 | 201 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 2 | 2020 | 49 | 0.170 |
Why?
|
| Interpersonal Relations | 2 | 2017 | 222 | 0.170 |
Why?
|
| Hip Fractures | 2 | 2019 | 29 | 0.170 |
Why?
|
| Mental Status Schedule | 5 | 2016 | 18 | 0.170 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 29 | 0.170 |
Why?
|
| Proteomics | 1 | 2023 | 378 | 0.160 |
Why?
|
| Body Composition | 3 | 2017 | 159 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2020 | 574 | 0.160 |
Why?
|
| Autopsy | 7 | 2019 | 48 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2020 | 16 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2014 | 27 | 0.160 |
Why?
|
| Chi-Square Distribution | 6 | 2014 | 236 | 0.160 |
Why?
|
| Carbonated Beverages | 1 | 2019 | 21 | 0.160 |
Why?
|
| Constipation | 3 | 2009 | 7 | 0.160 |
Why?
|
| Walking | 4 | 2010 | 88 | 0.160 |
Why?
|
| Adiponectin | 2 | 2012 | 59 | 0.150 |
Why?
|
| Emigrants and Immigrants | 2 | 2020 | 158 | 0.150 |
Why?
|
| Neuroglia | 1 | 2020 | 133 | 0.150 |
Why?
|
| Prognosis | 5 | 2015 | 861 | 0.150 |
Why?
|
| Frail Elderly | 2 | 2012 | 18 | 0.150 |
Why?
|
| Family Characteristics | 1 | 2020 | 126 | 0.150 |
Why?
|
| Arteries | 2 | 2014 | 81 | 0.150 |
Why?
|
| Forecasting | 2 | 2014 | 136 | 0.150 |
Why?
|
| Heptachlor Epoxide | 1 | 2018 | 1 | 0.150 |
Why?
|
| Bone Density | 1 | 2019 | 103 | 0.150 |
Why?
|
| Regression Analysis | 5 | 2012 | 490 | 0.150 |
Why?
|
| Neurons | 3 | 2015 | 1263 | 0.150 |
Why?
|
| Confidence Intervals | 8 | 2015 | 162 | 0.150 |
Why?
|
| Multilingualism | 2 | 2010 | 52 | 0.140 |
Why?
|
| Group Processes | 1 | 2018 | 23 | 0.140 |
Why?
|
| Abdominal Fat | 1 | 2018 | 21 | 0.140 |
Why?
|
| Social Support | 2 | 2013 | 445 | 0.140 |
Why?
|
| Referral and Consultation | 2 | 2016 | 142 | 0.140 |
Why?
|
| Cholesterol, LDL | 4 | 2021 | 73 | 0.140 |
Why?
|
| Pennsylvania | 5 | 2017 | 43 | 0.140 |
Why?
|
| Veterans | 3 | 2016 | 210 | 0.140 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 65 | 0.140 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 19 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 20 | 0.130 |
Why?
|
| Olfaction Disorders | 2 | 2008 | 12 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 291 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2012 | 246 | 0.130 |
Why?
|
| Population | 1 | 2016 | 8 | 0.130 |
Why?
|
| Hyperthyroidism | 1 | 2016 | 8 | 0.130 |
Why?
|
| Age of Onset | 2 | 2015 | 114 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2016 | 26 | 0.120 |
Why?
|
| C-Reactive Protein | 4 | 2015 | 167 | 0.120 |
Why?
|
| Polysomnography | 2 | 2014 | 43 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2016 | 72 | 0.120 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2007 | 11 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 54 | 0.120 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.120 |
Why?
|
| Diet Surveys | 3 | 2012 | 99 | 0.120 |
Why?
|
| Milk | 1 | 2015 | 56 | 0.120 |
Why?
|
| Menopause | 1 | 2015 | 64 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 229 | 0.110 |
Why?
|
| Phenotype | 5 | 2020 | 780 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 316 | 0.110 |
Why?
|
| Gene Frequency | 4 | 2018 | 206 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2016 | 210 | 0.110 |
Why?
|
| Vitamins | 1 | 2015 | 81 | 0.110 |
Why?
|
| Insulin | 2 | 2014 | 258 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2012 | 575 | 0.110 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 118 | 0.110 |
Why?
|
| Hemoglobins | 2 | 2015 | 113 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2021 | 368 | 0.110 |
Why?
|
| Environment | 2 | 2018 | 149 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 23 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2014 | 21 | 0.100 |
Why?
|
| Checklist | 1 | 2014 | 17 | 0.100 |
Why?
|
| Psychometrics | 3 | 2011 | 358 | 0.100 |
Why?
|
| Body Height | 1 | 2014 | 53 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 13 | 0.100 |
Why?
|
| Palau | 1 | 2013 | 9 | 0.100 |
Why?
|
| Energy Intake | 3 | 2015 | 164 | 0.100 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2013 | 1 | 0.100 |
Why?
|
| Primary Prevention | 2 | 2012 | 63 | 0.100 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2013 | 28 | 0.100 |
Why?
|
| Prions | 1 | 2013 | 23 | 0.100 |
Why?
|
| Nutritional Status | 3 | 2012 | 119 | 0.100 |
Why?
|
| Hand Strength | 2 | 2011 | 40 | 0.100 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 719 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2012 | 452 | 0.100 |
Why?
|
| Depressive Disorder | 2 | 2006 | 187 | 0.100 |
Why?
|
| Nutrition Disorders | 1 | 2012 | 12 | 0.100 |
Why?
|
| Cost Control | 1 | 2012 | 9 | 0.100 |
Why?
|
| Aortography | 3 | 2019 | 10 | 0.100 |
Why?
|
| Coffee | 2 | 2011 | 20 | 0.100 |
Why?
|
| Education, Nursing, Continuing | 1 | 2012 | 14 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 587 | 0.100 |
Why?
|
| Thromboembolism | 1 | 2012 | 20 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2013 | 77 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 201 | 0.090 |
Why?
|
| Program Development | 1 | 2013 | 240 | 0.090 |
Why?
|
| Health Services Misuse | 1 | 2012 | 20 | 0.090 |
Why?
|
| Open Reading Frames | 1 | 2012 | 79 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2012 | 34 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2011 | 338 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2014 | 321 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2011 | 18 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 12 | 0.090 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Ankle Brachial Index | 3 | 2016 | 11 | 0.090 |
Why?
|
| Systole | 4 | 2017 | 67 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2011 | 63 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2023 | 21 | 0.090 |
Why?
|
| Geriatric Nursing | 1 | 2010 | 2 | 0.080 |
Why?
|
| Teaching | 1 | 2011 | 59 | 0.080 |
Why?
|
| Caffeine | 1 | 2011 | 28 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2012 | 169 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2013 | 760 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 55 | 0.080 |
Why?
|
| Heat-Shock Proteins | 2 | 2023 | 57 | 0.080 |
Why?
|
| Models, Neurological | 1 | 2011 | 136 | 0.080 |
Why?
|
| Hospices | 1 | 2010 | 5 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2021 | 13 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 48 | 0.080 |
Why?
|
| Memory Disorders | 1 | 2010 | 77 | 0.080 |
Why?
|
| Antioxidants | 2 | 2004 | 443 | 0.080 |
Why?
|
| Risk | 6 | 2005 | 287 | 0.080 |
Why?
|
| Health Surveys | 1 | 2011 | 405 | 0.080 |
Why?
|
| Writing | 1 | 2009 | 42 | 0.080 |
Why?
|
| Solvents | 1 | 2010 | 113 | 0.080 |
Why?
|
| Ethics Consultation | 1 | 2008 | 4 | 0.070 |
Why?
|
| Metals | 1 | 2010 | 114 | 0.070 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Arthritis | 1 | 2009 | 18 | 0.070 |
Why?
|
| Aptitude | 1 | 2008 | 7 | 0.070 |
Why?
|
| Age Distribution | 4 | 2012 | 249 | 0.070 |
Why?
|
| Residence Characteristics | 2 | 2009 | 363 | 0.070 |
Why?
|
| Fatty Acids | 2 | 2022 | 134 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 16 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 1 | 2008 | 111 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 37 | 0.070 |
Why?
|
| Psychomotor Performance | 2 | 2006 | 159 | 0.070 |
Why?
|
| Cerebral Infarction | 2 | 2005 | 19 | 0.070 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 6 | 0.070 |
Why?
|
| Thyroid Gland | 1 | 2007 | 23 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 195 | 0.070 |
Why?
|
| Gynecology | 1 | 2007 | 35 | 0.070 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 42 | 0.070 |
Why?
|
| Haplotypes | 2 | 2018 | 197 | 0.070 |
Why?
|
| Neocortex | 1 | 2007 | 27 | 0.070 |
Why?
|
| Obstetrics | 1 | 2007 | 43 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 59 | 0.060 |
Why?
|
| Intracranial Embolism | 2 | 2004 | 2 | 0.060 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2006 | 4 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 5 | 0.060 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 40 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 375 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 23 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 6 | 0.060 |
Why?
|
| Mass Screening | 3 | 2008 | 541 | 0.060 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 20 | 0.060 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 423 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2006 | 90 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 55 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 72 | 0.060 |
Why?
|
| Ascorbic Acid | 2 | 2004 | 74 | 0.060 |
Why?
|
| Vitamin E | 2 | 2004 | 62 | 0.060 |
Why?
|
| Physicians | 1 | 2008 | 188 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2006 | 90 | 0.060 |
Why?
|
| Decision Making | 1 | 2008 | 249 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 165 | 0.060 |
Why?
|
| Brain Infarction | 2 | 2016 | 22 | 0.060 |
Why?
|
| Leisure Activities | 1 | 2025 | 41 | 0.060 |
Why?
|
| Patient Simulation | 1 | 2025 | 14 | 0.060 |
Why?
|
| Estrogens | 1 | 2006 | 203 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 611 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 82 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 42 | 0.050 |
Why?
|
| Social Behavior | 1 | 2006 | 161 | 0.050 |
Why?
|
| Feeding Behavior | 2 | 2008 | 469 | 0.050 |
Why?
|
| Parkinsonian Disorders | 1 | 2004 | 42 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2024 | 26 | 0.050 |
Why?
|
| Magnesium Deficiency | 1 | 2003 | 2 | 0.050 |
Why?
|
| Triglycerides | 2 | 2015 | 147 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 2157 | 0.050 |
Why?
|
| Tetanus | 1 | 2003 | 3 | 0.050 |
Why?
|
| Reference Values | 3 | 2014 | 211 | 0.050 |
Why?
|
| Thinness | 2 | 2014 | 32 | 0.050 |
Why?
|
| Memory | 1 | 2005 | 174 | 0.050 |
Why?
|
| Survival Rate | 2 | 2016 | 355 | 0.050 |
Why?
|
| Magnesium | 1 | 2003 | 94 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 40 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 55 | 0.050 |
Why?
|
| Students, Medical | 1 | 2005 | 158 | 0.050 |
Why?
|
| Young Adult | 1 | 2013 | 5080 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 70 | 0.050 |
Why?
|
| Nutrition Assessment | 2 | 2013 | 80 | 0.050 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2002 | 2 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2021 | 389 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 67 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2002 | 26 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2002 | 25 | 0.050 |
Why?
|
| Education, Medical | 2 | 2018 | 118 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 183 | 0.050 |
Why?
|
| Animals | 4 | 2022 | 16992 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2002 | 31 | 0.040 |
Why?
|
| Postmortem Changes | 3 | 2007 | 18 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 112 | 0.040 |
Why?
|
| Linear Models | 2 | 2012 | 317 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1081 | 0.040 |
Why?
|
| Brachial Artery | 2 | 2014 | 27 | 0.040 |
Why?
|
| Culture | 1 | 2002 | 172 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2012 | 224 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2020 | 32 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 65 | 0.040 |
Why?
|
| Diabetes Complications | 2 | 2016 | 102 | 0.040 |
Why?
|
| Micronesia | 1 | 2020 | 90 | 0.040 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2019 | 7 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 21 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 162 | 0.040 |
Why?
|
| Calcium | 2 | 2015 | 491 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2019 | 61 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 266 | 0.040 |
Why?
|
| Sirtuins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 86 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 83 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2012 | 317 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 423 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 52 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2008 | 123 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 46 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2011 | 195 | 0.030 |
Why?
|
| Early Diagnosis | 2 | 2008 | 68 | 0.030 |
Why?
|
| Laminin | 1 | 2017 | 58 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 47 | 0.030 |
Why?
|
| Inflammation | 1 | 2002 | 758 | 0.030 |
Why?
|
| Cell Count | 2 | 2009 | 145 | 0.030 |
Why?
|
| Genome, Human | 1 | 2017 | 144 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 403 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 97 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 91 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 110 | 0.030 |
Why?
|
| Chromatin | 1 | 2017 | 186 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 18 | 0.030 |
Why?
|
| France | 1 | 2015 | 23 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2015 | 8 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 44 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 671 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 20 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 983 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 34 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2015 | 35 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 34 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 29 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 103 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 113 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 95 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 163 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2015 | 117 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 100 | 0.030 |
Why?
|
| Plethysmography | 1 | 2014 | 6 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 8 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2014 | 12 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 56 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 341 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 36 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 384 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1082 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2013 | 5 | 0.030 |
Why?
|
| Genes, jun | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2017 | 561 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 22 | 0.030 |
Why?
|
| Exodeoxyribonucleases | 1 | 2013 | 17 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 48 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 81 | 0.020 |
Why?
|
| Organ Size | 1 | 2013 | 170 | 0.020 |
Why?
|
| Iceland | 1 | 2012 | 5 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 204 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 238 | 0.020 |
Why?
|
| Compliance | 1 | 2012 | 14 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 254 | 0.020 |
Why?
|
| Seafood | 1 | 2012 | 26 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2012 | 28 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 33 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 2011 | 9 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 199 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 35 | 0.020 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2011 | 5 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 101 | 0.020 |
Why?
|
| Hemosiderosis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Tea | 1 | 2011 | 46 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 456 | 0.020 |
Why?
|
| Language Tests | 1 | 2010 | 23 | 0.020 |
Why?
|
| Speech | 1 | 2010 | 16 | 0.020 |
Why?
|
| Men's Health | 1 | 2010 | 13 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 111 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 511 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 41 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 78 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 107 | 0.020 |
Why?
|
| Diagnosis | 1 | 2009 | 10 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 2009 | 17 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 408 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 89 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 89 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6081 | 0.020 |
Why?
|
| Defensive Medicine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Advance Directive Adherence | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tunica Media | 1 | 2008 | 15 | 0.020 |
Why?
|
| Medical Futility | 1 | 2008 | 10 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2008 | 22 | 0.020 |
Why?
|
| Professional Practice Location | 1 | 2008 | 17 | 0.020 |
Why?
|
| Health | 1 | 2008 | 30 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2008 | 29 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 26 | 0.020 |
Why?
|
| Olfactory Pathways | 1 | 2008 | 14 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 104 | 0.020 |
Why?
|
| Pick Disease of the Brain | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2007 | 4 | 0.020 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2007 | 13 | 0.020 |
Why?
|
| Medicine | 1 | 2008 | 37 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 712 | 0.020 |
Why?
|
| Smell | 1 | 2008 | 40 | 0.020 |
Why?
|
| Thyroxine | 1 | 2007 | 22 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 71 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 374 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 24 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 509 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 61 | 0.020 |
Why?
|
| Cuba | 1 | 2006 | 33 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 64 | 0.020 |
Why?
|
| Gels | 1 | 2006 | 45 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 89 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2006 | 38 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2007 | 150 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 215 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 22 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 47 | 0.020 |
Why?
|
| Pulse | 1 | 2005 | 7 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2006 | 38 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 74 | 0.010 |
Why?
|
| Postural Balance | 1 | 2006 | 37 | 0.010 |
Why?
|
| Weight Gain | 1 | 2007 | 139 | 0.010 |
Why?
|
| Public Health | 1 | 2010 | 424 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 125 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1604 | 0.010 |
Why?
|
| Registries | 1 | 2007 | 437 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 233 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 429 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2006 | 282 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 45 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 116 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 638 | 0.010 |
Why?
|
| beta Carotene | 1 | 2004 | 11 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 76 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 107 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 60 | 0.010 |
Why?
|
| Health Promotion | 1 | 2010 | 704 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 28 | 0.010 |
Why?
|
| Flavonoids | 1 | 2004 | 100 | 0.010 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2002 | 1 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2006 | 380 | 0.010 |
Why?
|
| World Health Organization | 1 | 2002 | 36 | 0.010 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 4 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 114 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2002 | 74 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 23 | 0.010 |
Why?
|
| Atrophy | 1 | 2002 | 51 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2003 | 256 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 237 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 1003 | 0.010 |
Why?
|